PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportstriple negative breast neoplasms
MeSH D064726 - triple negative breast neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D001943:Breast neoplasms
197 Companies
87 Drugs
$
Success rate
D064726: 
Triple negative breast neoplasms
2 Companies
3 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Gilead SciencesSacituzumab govitecan Trodelvy  2020-04-22 $1,259 M Q4/23-Q3/24 
Merck & CoPembrolizumab Keytruda  2014-09-04 $31,139 M Q4/24-Q3/25 
Clinical Trials
Historical Success Rate
Phase 1
72%
116/161
Phase 2
26%
49/186
Phase 3
9%
6/64
Approved: 4Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Gilead Sciences
Sacituzumab govitecan,
Sacituzumab,
Rucaparib,
Rucaparib camsylate,
Magrolimab,
Ivuxolimab,
Utomilumab,
Zimberelimab,
Lucitanib,
Lenograstim,
Edrecolomab,
Lornoxicam,
Molgramostim,
Bevifimod,
Doxecitine,
Nepidermin,
Globulin, immune,
Krestin,
Doxorubin,
Mk3475,
Al3810,
Antineoplaston a10,
Histone-arginine methyltransferase carm1,
Hydroxydaunomycin,
Surlorian,
Taxane
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use